Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis

References

• FDA Approval for Everolimus. 2016.
   Google Scholar
• Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005–12.
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.
   PubMed Web of Science ®Google Scholar
• Andre F, O'regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014;15:580–91.
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520–9.
   PubMed Web of Science ®Google Scholar
• Beckner ME, Stracke ML, Liotta LA, Schiffmann E. Glycolysis as primary energy source in tumor cell chemotaxis. J Natl Cancer Inst 1990;82:1836–40.
   PubMed Web of Science ®Google Scholar
• Duan W, Shen X, Lei J, Xu Q, Yu Y, Li R, et al. Hyperglycemia, a neglected factor during cancer progression. BioMed Res Int 2014;2014. doi:http://dx.doi.org/10.1155/2014/461917.
   Web of Science ®Google Scholar
• Masur K, Vetter C, Hinz A, Tomas N, Henrich H, Niggemann B, et al. Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Br J Cancer 2011;104:345–52.
   PubMed Web of Science ®Google Scholar
• Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol 2009;15:4137–42.
   PubMed Web of Science ®Google Scholar
• Bloom RD, Crutchlow MF. Transplant-associated hyperglycemia. Transplant. Transplant Rev (Orlando) 2008;22:39–51.
   PubMedGoogle Scholar
• Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K, et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) +/- bevacizumab - results of the randomised GeparQuinto study (GBG 44). Eur J Cancer 2013;49:2284–93.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014;312:57–67.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
   PubMedGoogle Scholar
• Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487–94.
   PubMed Web of Science ®Google Scholar
• Shameem R, Lacouture M, Wu S. Incidence and risk of rash to mTOR inhibitors in cancer patients-a meta-analysis of randomized controlled trials. Acta Oncol 2015;54:124–32.
   PubMed Web of Science ®Google Scholar
• Institute NC. Common Toxicity Criteria (CTC), Common Terminology Criteria for Adverse Events Version 4.0, 2009.
   Google Scholar
• Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630–7.
   PubMed Web of Science ®Google Scholar
• Besse B, Leighl N, Bennouna J, Papadimitrakopoulou VA, Blais N, Traynor AM, et al. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol 2014;25:409–15.
   PubMed Web of Science ®Google Scholar
• Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 2003;285:E685–92.
   PubMed Web of Science ®Google Scholar
• Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010;16:3628–38.
   PubMed Web of Science ®Google Scholar
• Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004;431:200–5.
   PubMed Web of Science ®Google Scholar
• Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab 2001;3:393–402.
   PubMed Web of Science ®Google Scholar
• Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes? J Am Soc Nephrol 2006;17:2236–44.
   PubMed Web of Science ®Google Scholar
• Leibiger IB, Leibiger B, Moede T, Berggren PO. Exocytosis of insulin promotes insulin gene transcription via the insulin receptor/PI-3 kinase/p70 s6 kinase and CaM kinase pathways. Mol Cell 1998;1:933–8.
   PubMed Web of Science ®Google Scholar
• Johnson EK, Klotz AD, Vaze AA, Grasso V. Nephrologic and Urologic Emergencies. In: Yeung SJ, Escalante CP, editors. Oncologic Emergencies. Hamilton, ON, Canada: B. C. Decker Inc; 2002. p. 280–303.
   Google Scholar
• Grgic T, Mis L, Hammond JM. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma. Ann Pharmacother 2011;45:78–83.
   PubMed Web of Science ®Google Scholar
• Kahn CR. The riddle of tumour hypoglycaemia revisited. Clin Endocrinol Metab 1980;9:335–60.
   PubMedGoogle Scholar
• Novartis. Full prescribing information for Affinitor, 2015.
   Google Scholar